Globus Medical Inc. (NYSE:GMED), a medical device company with a market capitalization of $12 billion and an "GREAT" financial health rating according to InvestingPro, reaffirmed its commitment to ...

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...

The Globus-M and now -M2 are primarily for scientific research and technology demonstration. They show the potential for spherical tokamaks to generate hybrid fusion-fission nuclear power.

Stryker sold its U.S. spinal implants to the Viscogliosi Brothers, and market analysts with GlobalData predict the move will benefit competitors in spinal fusio ...